Fas Ligand Antibody

ELISA, WB, Neutralization Assay

Fas Ligand antibody is stable for at least 2 years from date of receipt at -20˚ C. The reconstituted antibody is stable for at least two weeks at 2-8˚ C. Frozen aliquots are stable for at least 6 months when stored at -20˚ C. Avoid repeated freeze-thaw cycles.

Fas Ligand is an important member of the tumour necrosis factor (TNF) superfamily involved in membrane mediated apoptosis. Ligation of Fas by Fas Ligand or an anti Fas cross linking antibody, triggers activation of the caspase cascade. Functional impairment of the Fas / Fas Ligand system is associated with the development and progression of malignancies. Fas gene mutations have been suggested to have a role in testicular germ cell tumors. Tumor cells frequently exhibit de novo expression of Fas Ligand, which plays a significant role in local tissue destruction, metastatic spread, and immune escape of the tumor cells. The apoptosis of lymphocytes, which occurs in autoimmune diseases, is usually induced by the Fas/Fas Ligand system.

None

Anti-hFasL specific antibody was purified by affinity chromatography employing immobilized hFasL matrix.

Neutralization:
To yield one-half maximal inhibition [ND50] of the biological activity of FasL/Apo1L (10 ng/mL), a concentration of 0.08 - 0.1 μ g/mL of this antibody is required. ELISA:
To detect hFasL by direct ELISA (using 100 μ L/well antibody solution) a concentration of at least 0.5 μ g/mL of this antibody is required. This antigen affinity purified antibody, in conjunction with compatible secondary reagents, allows the detection of 0.2 - 0.4 ng/well of recombinant hFasL.
Western Blot:
To detect hFasL by Western Blot analysis this antibody can be used at a concentration of 0.1 - 0.2 μ g/mL. Used in conjunction with compatible secondary reagents the detection limit for recombinant hFasL is 1.5 - 3.0 ng/lane, under either reducing or non-reducing conditions.

Polyclonal

Homo sapiens

Centrifuge vial prior to opening.